CS
DICE

Candriam SCA’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Candriam SCA’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-210,000
Closed -$5.54M – 895
2023
Q1 		$5.54M Hold
210,000
– – 0.04% 342
2022
Q4 		$6.55M Buy
+210,000
New +$6.85M 0.04% 338

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Candriam SCA's DICE Position: Q2 2023 in Review

Candriam SCA sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q2 2023, closing a stake of 210,000 shares — an estimated $5.54M sold.

Candriam SCA first reported a position in DICE in Q4 2022 and held it in 2 quarters. The position peaked at $6.55M in Q4 2022. 160 funds tracked by Wall St. Rank hold DICE as of Q2 2023.

  • Candriam SCA reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Candriam SCA sold 210,000 DICE Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $5.54M.
  • Candriam SCA first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Candriam SCA's DICE Therapeutics, Inc. Common Stock position peaked at $6.55M in Q4 2022.
  • 160 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.